Impact of Travel Burden on Timeliness of Care and Overall Survival for Breast Cancer: A National Cancer Database Analysis
Cancer Medicine · 2025-11 · 14 (21)
DOI: 10.1002/cam4.71354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.11.2025. Verfasst von Yongzhe Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Travel, Time-to-Treatment, Health Services Accessibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Breast Cancer Research Foundation, NIH HHS.
Abstract (Originalsprache)
Introduction
Timely treatment initiation is critical to clinical outcomes in breast cancer (BC). While social determinants of health are established drivers of disparities in the timeliness of care (ToC), the impact of travel burden remains less defined. This study evaluates associations between travel burden, ToC, and overall survival (OS) in a nationally representative BC cohort.
Methods
We analyzed 283,166 BC patients from the National Cancer Database (2004–2021) with documented great circle distance (GCD), categorized as ≤ 10, 10.1–20.0, and > 20 miles. Associations between GCD and ToC—defined as time from diagnosis to first treatment and categorized as < 8, 8–12, and > 12 weeks—were assessed using negative binomial models, and associations with OS were evaluated using Cox models.
Results
Compared to patients with GCD < 10 miles, patients with GCD > 20 miles experienced delays in ToC when diagnosed with early‐stage disease, especially when undergoing surgery as first treatment (RR: 1.05, 95% CI: 1.04–1.06). Compared to treatment within 8 weeks of diagnosis, treatment initiation > 12 weeks had 24% higher mortality (HR: 1.24, 95% CI: 1.14–1.35), especially among patients receiving surgery (HR: 1.31, 95% CI: 1.19–1.43) and chemotherapy (HR: 1.30, 95% CI: 1.18–1.43). Even surgery within 8–12 weeks carried an elevated risk (HR: 1.09, 95% CI: 1.02–1.16). Metropolitan patients with GCD > 20 miles had a 12% lower mortality (HR: 0.88, 95% CI: 0.81–0.96) than those ≤ 10 miles away; no such differences were observed in urban or rural groups.
Conclusion
Travel burden influences BC ToC and OS through geographic, clinical, and facility factors, underscoring the need for tailored interventions that address local care capacity, patient demographics, and disease profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, City of Hope, Duarte, California, USA.
- School of Medicine, University of California, Riverside, Riverside, California, USA.
ORCID-Profile: Yongzhe Wang, Veronica C Jones
Förderung
- NCI NIH HHS
- Breast Cancer Research Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Wang, Y., Quinones, C. M., Gonzalez, E., Farmah, P., Schoellhammer, H. F., Gonzalez, L., Shah, N., Schulz-Costello, K., Tseng, J., & Jones, V. C. (2025). Impact of Travel Burden on Timeliness of Care and Overall Survival for Breast Cancer: A National Cancer Database Analysis. Cancer Medicine, 14(21). https://doi.org/10.1002/cam4.71354
Vancouver
Wang Y, Quinones CM, Gonzalez E, Farmah P, Schoellhammer HF, Gonzalez L, et al. Impact of Travel Burden on Timeliness of Care and Overall Survival for Breast Cancer: A National Cancer Database Analysis. Cancer Medicine. 2025;14(21). doi:10.1002/cam4.71354
BibTeX
@article{Wang2025,
author = {Wang, Yongzhe and Quinones, Christine M and Gonzalez, Elizabeth and Farmah, Preeti and Schoellhammer, Hans F and Gonzalez, Lorena and Shah, Nikita and Schulz-Costello, Katharine and Tseng, Jennifer and Jones, Veronica C},
title = {Impact of Travel Burden on Timeliness of Care and Overall Survival for Breast Cancer: A National Cancer Database Analysis},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {21},
doi = {10.1002/cam4.71354}
}
EUVIMED